Brain

Qanatpharma, Zuse Institute Berlin, Enamine, and Proteros biostructures Announce Generative-AI Driven Lead Discovery Collaboration

Joint research program targets new treatments for life-threatening complication of brain hemorrhage An international discovery collaboration is harnessing AI-powered drug…

5 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial  Recent…

5 months ago

Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements

NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech…

5 months ago

BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company…

5 months ago

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug FilingKANSAS CITY, Kan., July…

5 months ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare…

5 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted…

5 months ago

PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),…

5 months ago